SG11201704058TA - Cd47 antibodies, methods, and uses - Google Patents
Cd47 antibodies, methods, and usesInfo
- Publication number
- SG11201704058TA SG11201704058TA SG11201704058TA SG11201704058TA SG11201704058TA SG 11201704058T A SG11201704058T A SG 11201704058TA SG 11201704058T A SG11201704058T A SG 11201704058TA SG 11201704058T A SG11201704058T A SG 11201704058TA SG 11201704058T A SG11201704058T A SG 11201704058TA
- Authority
- SG
- Singapore
- Prior art keywords
- antibodies
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462081134P | 2014-11-18 | 2014-11-18 | |
| PCT/US2015/061014 WO2016081423A1 (en) | 2014-11-18 | 2015-11-17 | Cd47 antibodies, methods, and uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201704058TA true SG11201704058TA (en) | 2017-06-29 |
Family
ID=54705894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201704058TA SG11201704058TA (en) | 2014-11-18 | 2015-11-17 | Cd47 antibodies, methods, and uses |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10864268B2 (en) |
| EP (1) | EP3221358B1 (en) |
| JP (1) | JP6857603B2 (en) |
| KR (1) | KR20170081699A (en) |
| CN (1) | CN107406503B (en) |
| AU (1) | AU2015350190B2 (en) |
| BR (1) | BR112017010303A2 (en) |
| CA (1) | CA2967379A1 (en) |
| EA (1) | EA201791093A1 (en) |
| IL (1) | IL252198A0 (en) |
| MX (1) | MX2017006485A (en) |
| PH (1) | PH12017500915A1 (en) |
| SG (1) | SG11201704058TA (en) |
| WO (1) | WO2016081423A1 (en) |
| ZA (1) | ZA201704117B (en) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
| IL254039B2 (en) | 2015-02-19 | 2023-12-01 | Compugen Ltd | Anti-PVRIG antibodies and methods of use |
| GEP20217326B (en) | 2015-08-07 | 2021-11-25 | Alx Oncology Inc | Constructs having a sirp-alpha domain or variant thereof |
| WO2017184553A1 (en) * | 2016-04-18 | 2017-10-26 | Baylor College Of Medicine | Cancer gene therapy targeting cd47 |
| CN106084052B (en) * | 2016-06-17 | 2019-12-27 | 长春金赛药业股份有限公司 | anti-CD 47 monoclonal antibody and application thereof |
| US12344669B2 (en) | 2016-06-17 | 2025-07-01 | Changchun Genescience Pharmaceutical Co., Ltd. | Anti-CD47 monoclonal antibody and use thereof |
| CA3029977A1 (en) | 2016-07-06 | 2018-01-11 | Celgene Corporation | Antibodies with low immunogenicity and uses thereof |
| WO2018012952A1 (en) * | 2016-07-15 | 2018-01-18 | 한국과학기술연구원 | Novel nanocage and use thereof |
| CN114773471A (en) * | 2016-10-20 | 2022-07-22 | 天境生物科技(上海)有限公司 | Novel CD47 monoclonal antibody and application thereof |
| EP3534965A4 (en) | 2016-11-03 | 2020-06-24 | Trillium Therapeutics Inc. | IMPROVEMENTS IN CD47 BLOCKADERAPY THROUGH HDAC INHIBITORS |
| NZ761568A (en) * | 2017-08-02 | 2022-11-25 | Phanes Therapeutics Inc | Anti-cd47 antibodies and uses thereof |
| CN117820498A (en) * | 2017-08-10 | 2024-04-05 | 盖立复诊断解决方案公司 | Compositions, methods and/or kits comprising recombinant human CD38 extracellular domain |
| JP7256580B2 (en) * | 2017-08-18 | 2023-04-12 | ウルトラヒューマン フォー リミティド | binder |
| EP3710048A4 (en) * | 2017-11-17 | 2021-08-18 | University of Massachusetts | HUMANIZED MONOCLONAL 2C7 ANTIBODIES AGAINST ANEISSERIA GONORRHOEAE |
| AU2018375375A1 (en) | 2017-12-01 | 2020-05-28 | Seagen Inc. | CD47 antibodies and uses thereof for treating cancer |
| CN110144009B (en) * | 2018-02-14 | 2020-01-21 | 上海洛启生物医药技术有限公司 | CD47 single domain antibodies and uses thereof |
| GB201804860D0 (en) * | 2018-03-27 | 2018-05-09 | Ultrahuman Two Ltd | CD47 Binding agents |
| CN110577597B (en) * | 2018-06-11 | 2021-10-22 | 康诺亚生物医药科技（成都）有限公司 | An antibody that blocks the interaction of CD47 and SIRPα |
| CN112566662A (en) | 2018-06-15 | 2021-03-26 | 阿库鲁斯生物科学公司 | Blocking antibodies against CD47 and methods of use thereof |
| CN109053882B (en) * | 2018-08-28 | 2019-08-23 | 东莞市朋志生物科技有限公司 | A binding protein of NS1 protein and application |
| WO2020043188A1 (en) * | 2018-08-31 | 2020-03-05 | 南京圣和药业股份有限公司 | Anti-cd47 antibody and application thereof |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| WO2020097193A1 (en) | 2018-11-06 | 2020-05-14 | The Regents Of The University Of California | Chimeric antigen receptors for phagocytosis |
| PH12021552030A1 (en) | 2019-02-26 | 2022-08-15 | Janssen Biotech Inc | Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies |
| CN114072172B (en) * | 2019-04-18 | 2025-05-13 | Qlsf生物治疗药物公司 | Antibodies targeting human CD47 |
| US11026973B2 (en) | 2019-04-30 | 2021-06-08 | Myeloid Therapeutics, Inc. | Engineered phagocytic receptor compositions and methods of use thereof |
| US11879013B2 (en) | 2019-05-14 | 2024-01-23 | Janssen Biotech, Inc. | Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors |
| AU2020282791A1 (en) | 2019-05-31 | 2021-12-09 | ALX Oncology Inc. | Methods of treating cancer with SIRP alpha Fc fusion in combination with an immune checkpoint inhibitor |
| EP3980747A1 (en) | 2019-06-07 | 2022-04-13 | ALX Oncology Inc. | Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays |
| AU2020315598B2 (en) | 2019-07-16 | 2024-12-12 | Gilead Sciences, Inc. | HIV vaccines and methods of making and using |
| GB2628935B (en) | 2019-09-03 | 2025-03-05 | Myeloid Therapeutics Inc | Methods and compositions for genomic integration |
| CN118178645A (en) | 2019-10-18 | 2024-06-14 | 四十七公司 | Combination therapy for the treatment of myelodysplastic syndrome and acute myeloid leukemia |
| AU2020372522B2 (en) * | 2019-10-25 | 2024-08-15 | WuXi Biologics Ireland Limited | Novel anti-CD47 antibodies and uses thereof |
| KR20220091576A (en) | 2019-10-31 | 2022-06-30 | 포티 세븐, 인코포레이티드 | Anti-CD47 and Anti-CD20 Based Treatment of Hematological Cancers |
| BR112022008817A2 (en) | 2019-11-27 | 2022-07-26 | Alx Oncology Inc | COMBINED THERAPIES FOR CANCER TREATMENT |
| GB201918230D0 (en) | 2019-12-11 | 2020-01-22 | Prec Therapeutics Ltd | Antibodies and their uses |
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| HRP20241518T1 (en) | 2019-12-24 | 2025-01-03 | Carna Biosciences, Inc. | Diacylglycerol kinase modulating compounds |
| JOP20220184A1 (en) | 2020-02-12 | 2023-01-30 | Janssen Biotech Inc | TREATMENT OF PATIENTS HAVING c-MET EXON 14 SKIPPING MUTATIONS |
| PH12022552122A1 (en) | 2020-02-14 | 2024-01-29 | Jounce Therapeutics Inc | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
| AU2021243864A1 (en) | 2020-03-27 | 2022-11-03 | Mendus B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| CA3182607A1 (en) | 2020-06-30 | 2022-01-06 | Erik Hans MANTING | Use of leukemia-derived cells in ovarian cancer vaccines |
| JP7789304B2 (en) * | 2020-07-31 | 2025-12-22 | バイオ－テラ ソリュ－ションズ，エルティーディー． | CD47 antibody and its applications |
| WO2022098642A1 (en) | 2020-11-03 | 2022-05-12 | Rdiscovery, LLC | Therapies for treatment of cancer and phagocytosis-deficiency related diseases |
| WO2022098905A2 (en) | 2020-11-04 | 2022-05-12 | Myeloid Therapeutics, Inc. | Engineered chimeric fusion protein compositions and methods of use thereof |
| JP2023552375A (en) | 2020-12-06 | 2023-12-15 | エーエルエックス オンコロジー インコーポレイテッド | Multimers for reducing interference of drugs that bind to CD47 in serological assays |
| JP2024503822A (en) * | 2021-01-05 | 2024-01-29 | ナショナル インスティテュート オブ バイオロジカル サイエンシズ，ベイジン | Bispecific antibody targeting GPC3 and CD47 |
| US20250277031A1 (en) * | 2021-01-08 | 2025-09-04 | Beijing Hanmi Pharmaceutical Co., Ltd. | Antibody specifically binding to cd47 and antigen-binding fragment thereof |
| WO2022190058A1 (en) | 2021-03-12 | 2022-09-15 | Dcprime B.V. | Methods of vaccination and use of cd47 blockade |
| AU2022237618A1 (en) | 2021-03-17 | 2023-10-12 | Create Medicines, Inc. | Engineered chimeric fusion protein compositions and methods of use thereof |
| TW202302145A (en) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | Co-inhibition of cd47/sirpα binding and nedd8-activating enzyme e1 regulatory subunit for the treatment of cancer |
| JP2024518100A (en) | 2021-05-11 | 2024-04-24 | マイエロイド・セラピューティクス，インコーポレーテッド | Methods and compositions for genomic integration |
| CA3216908A1 (en) | 2021-05-13 | 2022-11-17 | ALX Oncology Inc. | Combination therapies for treating cancer |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| US11976072B2 (en) | 2021-06-23 | 2024-05-07 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| US11932634B2 (en) | 2021-06-23 | 2024-03-19 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| CN117881698A (en) * | 2021-06-30 | 2024-04-12 | 创新生物有限公司 | Humanized antibody specific to CD47 and pharmaceutical composition containing the same for preventing or treating CD47-related diseases |
| US20230183216A1 (en) | 2021-10-28 | 2023-06-15 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| CR20240173A (en) | 2021-10-29 | 2024-06-20 | Gilead Sciences Inc | CD73 COMPOUNDS |
| CN118488948A (en) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | IKAROS zinc finger family degraders and their uses |
| JP2024546851A (en) | 2021-12-22 | 2024-12-26 | ギリアード サイエンシーズ， インコーポレイテッド | IKAROS ZINC FINGER FAMILY DEGRADANT AND USES THEREOF |
| CN114371282B (en) * | 2021-12-30 | 2025-07-11 | 上海药明生物技术有限公司 | A method for evaluating the effect of antigen silencing on antibody efficacy and its application |
| TW202340168A (en) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7 inhibitors |
| JP2025509610A (en) | 2022-03-17 | 2025-04-11 | ギリアード サイエンシーズ， インコーポレイテッド | IKAROS ZINC FINGER FAMILY DEGRADANT AND USES THEREOF |
| WO2023183817A1 (en) | 2022-03-24 | 2023-09-28 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TWI876305B (en) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | Combination therapy for treating colorectal cancer |
| JP2025513258A (en) | 2022-04-21 | 2025-04-24 | ギリアード サイエンシーズ， インコーポレイテッド | KRA G12D modulating compounds |
| IL317958A (en) | 2022-07-01 | 2025-02-01 | Gilead Sciences Inc | Cd73 compounds |
| AU2023307100A1 (en) | 2022-07-12 | 2025-01-02 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
| US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
| WO2024124107A2 (en) | 2022-12-09 | 2024-06-13 | Pfizer Inc. | Cd47 blocking agent and anti-cd20 / anti-cd3 bispecific antibody combination therapy |
| JP2025540215A (en) | 2022-12-09 | 2025-12-11 | ファイザー・インク | Combination therapy of CD47 blocking agents and anti-BCMA/anti-CD3 bispecific antibodies |
| CN118221812A (en) * | 2022-12-14 | 2024-06-21 | 上海迈石生物技术有限公司 | CD 47-targeted monoclonal antibody and application thereof |
| KR20250122479A (en) | 2022-12-22 | 2025-08-13 | 길리애드 사이언시즈, 인코포레이티드 | PRMT5 inhibitors and uses thereof |
| AU2023415274A1 (en) * | 2022-12-29 | 2025-06-26 | Shanghai Henlius Biologics Co., Ltd. | Anti-cd47 antibodies and methods of use |
| EP4680639A1 (en) | 2023-03-13 | 2026-01-21 | Janssen Biotech, Inc. | Combination therapies with bi-specific anti-egfr/c-met antibodies and anti-pd-1 antibodies |
| CN120882725A (en) | 2023-04-11 | 2025-10-31 | 吉利德科学公司 | KRAS-regulated compounds |
| CN121079300A (en) | 2023-04-21 | 2025-12-05 | 吉利德科学公司 | PRMT5 inhibitors and their uses |
| WO2025006720A1 (en) | 2023-06-30 | 2025-01-02 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025024663A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025096589A1 (en) | 2023-11-03 | 2025-05-08 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| US20250376484A1 (en) | 2024-05-21 | 2025-12-11 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3068506A (en) | 1958-02-19 | 1962-12-18 | Trico Products Corp | Combined windshield cleaner and washer |
| US3068507A (en) | 1959-08-28 | 1962-12-18 | Babcock & Wilcox Ltd | Fluid heater cleaners |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DK0463151T3 (en) | 1990-01-12 | 1996-07-01 | Cell Genesys Inc | Generation of xenogenic antibodies |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| CA2098177A1 (en) | 1990-12-13 | 1992-06-13 | Jerry L. Adams | Csaids |
| KR100252547B1 (en) | 1991-09-05 | 2000-09-01 | 프레드 마리얀스키 | Targeted Delivery of Poly- or Oligonucleotides to Cells |
| DE69233782D1 (en) | 1991-12-02 | 2010-05-20 | Medical Res Council | Preparation of Autoantibodies on Phage Surfaces Starting from Antibody Segment Libraries |
| US5777085A (en) | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
| EP0592677B1 (en) | 1992-02-18 | 2001-11-07 | Otsuka Kagaku Kabushiki Kaisha | Beta-LACTAM COMPOUND AND CEPHEM COMPOUND, AND PRODUCTION THEREOF |
| US5233409A (en) | 1992-02-25 | 1993-08-03 | Schwab Karl W | Color analysis of organic constituents in sedimentary rocks for thermal maturity |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| EP0652950B1 (en) | 1992-07-24 | 2007-12-19 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
| JPH10501681A (en) | 1994-02-22 | 1998-02-17 | ダナ−ファーバー キャンサー インスティチュート | Nucleic acid delivery systems and methods for their synthesis and use |
| US5703057A (en) | 1995-04-07 | 1997-12-30 | Board Of Regents The University Of Texas System | Expression library immunization |
| AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| CA2273194C (en) | 1996-12-03 | 2011-02-01 | Abgenix, Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| US6472147B1 (en) | 1999-05-25 | 2002-10-29 | The Scripps Research Institute | Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries |
| US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| GB9930706D0 (en) * | 1999-12-24 | 2000-02-16 | Medical Res Council | Composition for inhibiting macrophage activity |
| CN1308447C (en) * | 2000-10-20 | 2007-04-04 | 中外制药株式会社 | Low molecular weight agonist antibody |
| EP1327681A4 (en) * | 2000-10-20 | 2004-09-01 | Chugai Pharmaceutical Co Ltd | DEGREE AGONIST ANTIBODIES |
| US8101719B2 (en) * | 2003-11-11 | 2012-01-24 | Chugai Seiyaku Kabushiki Kaisha | Humanized anti-CD47 antibody |
| EP1885399B1 (en) * | 2005-05-26 | 2010-10-20 | Seattle Genetics, Inc. | Humanized anti-cd40 antibodies and their methods of use |
| CA2710373A1 (en) | 2007-12-19 | 2009-07-09 | Ping Tsui | Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods |
| KR101791430B1 (en) | 2009-11-30 | 2017-10-30 | 얀센 바이오테크 인코포레이티드 | ANTIBODY Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS |
| LT3789038T (en) * | 2010-05-14 | 2022-12-12 | The Board Of Trustees Of The Leland Stanford Junior University | Humanized and chimeric monoclonal antibodies to cd47 |
| HUE050875T2 (en) * | 2012-01-17 | 2021-01-28 | Univ Leland Stanford Junior | High affinity SIRP-alpha reagents |
| EP3578569A1 (en) | 2012-02-06 | 2019-12-11 | Inhibrx, Inc. | Cd47 antibodies and methods of use thereof |
| JP6572131B2 (en) * | 2012-12-12 | 2019-09-04 | バスキュロックス インコーポレイテッド | CD47 antibody for treatment |
| US9873747B2 (en) * | 2013-01-31 | 2018-01-23 | Thomas Jefferson University | Fusion proteins that facilitate cancer cell destruction |
| PE20151408A1 (en) * | 2013-02-06 | 2015-10-15 | Inhibrx Llc | CD47 ANTIBODIES THAT DO NOT EXHAUST PLATELETS OR RED BALLOONS AND METHODS OF USING THEM |
-
2015
- 2015-11-17 SG SG11201704058TA patent/SG11201704058TA/en unknown
- 2015-11-17 AU AU2015350190A patent/AU2015350190B2/en not_active Ceased
- 2015-11-17 CN CN201580073804.7A patent/CN107406503B/en not_active Expired - Fee Related
- 2015-11-17 KR KR1020177016228A patent/KR20170081699A/en not_active Withdrawn
- 2015-11-17 EA EA201791093A patent/EA201791093A1/en unknown
- 2015-11-17 JP JP2017526534A patent/JP6857603B2/en not_active Expired - Fee Related
- 2015-11-17 US US15/527,551 patent/US10864268B2/en not_active Expired - Fee Related
- 2015-11-17 EP EP15801630.3A patent/EP3221358B1/en active Active
- 2015-11-17 CA CA2967379A patent/CA2967379A1/en not_active Abandoned
- 2015-11-17 MX MX2017006485A patent/MX2017006485A/en unknown
- 2015-11-17 WO PCT/US2015/061014 patent/WO2016081423A1/en not_active Ceased
- 2015-11-17 BR BR112017010303A patent/BR112017010303A2/en not_active Application Discontinuation
-
2017
- 2017-05-10 IL IL252198A patent/IL252198A0/en unknown
- 2017-05-17 PH PH12017500915A patent/PH12017500915A1/en unknown
- 2017-06-15 ZA ZA2017/04117A patent/ZA201704117B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US10864268B2 (en) | 2020-12-15 |
| ZA201704117B (en) | 2019-09-25 |
| CA2967379A1 (en) | 2016-05-26 |
| CN107406503B (en) | 2021-07-16 |
| CN107406503A (en) | 2017-11-28 |
| AU2015350190B2 (en) | 2021-08-05 |
| EA201791093A1 (en) | 2018-04-30 |
| IL252198A0 (en) | 2017-07-31 |
| PH12017500915A1 (en) | 2017-11-20 |
| BR112017010303A2 (en) | 2018-05-15 |
| AU2015350190A1 (en) | 2017-06-01 |
| US20180250395A1 (en) | 2018-09-06 |
| WO2016081423A1 (en) | 2016-05-26 |
| KR20170081699A (en) | 2017-07-12 |
| MX2017006485A (en) | 2018-03-23 |
| EP3221358A1 (en) | 2017-09-27 |
| EP3221358B1 (en) | 2021-07-21 |
| JP2018502060A (en) | 2018-01-25 |
| JP6857603B2 (en) | 2021-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL320713A (en) | Antibodies, uses and methods | |
| ZA201704117B (en) | Cd47 antibodies, methods, and uses | |
| IL317989A (en) | Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof | |
| ZA201704467B (en) | Anti-cd47 antibodies and uses thereof | |
| IL252804A0 (en) | Anti-c10orf54 antibodies and uses thereof | |
| IL251248A0 (en) | Anti-interleukin-33 antibodies and uses thereof | |
| ZA201605894B (en) | Anti-egfrviii antibodies and uses thereof | |
| EP3200823A4 (en) | Multivalent meditopes, meditope-binding antibodies and uses thereof | |
| IL252430A0 (en) | Antibodies, uses and methods | |
| ZA201701663B (en) | Anti-il-25 antibodies and uses thereof | |
| GB201618515D0 (en) | Combinations comprising antibodies, uses and methods | |
| GB201413950D0 (en) | Antibodies, uses & methods | |
| GB201400597D0 (en) | Antibodies, uses & methods |